全身化疗联合肝动脉栓塞灌注化疗治疗乳腺癌肝转移的效果

解华; 刘宏杰; 李凌云; 张华满; 解华; 刘宏杰; 李凌云; 张华满

doi:10.13898/j.cnki.issn.1000-2200.2016.11.022

[1]

JERNAL A,BRAY F,CENTER MM,et al.Global cancer statistics[J].CA Cancer J Clin,2011,61(2):69.

[2]

SIEGEL R,NAISHADHAM D,JERNAL A.Cancer statistics[J].CA Cancer J Clin,2013,63(1):11.

[3]

EISENHAUER EA,THERASSE P,BOGAERTS J,et al.New response evaluation criteria in solid tumours:vevisel RECIST guideline(version 1.1)[J].Eur J Cancer,2009,45(2):228.

[4]

孙燕,周际昌.临床肿瘤内科手册[M].4版.北京:人民卫生出版社,2004:44.

[5]

PENTHEROUDAKIS G,FOUNTZILAS G,BAFALOUKOS D,et al.Metastatic breast cancer with liver metastases:a registry analysis of clincopothologic,manager ment and outcom characteristis of 500 women[J].Breast Cancer Kes Treat,2006,97(3):237.

[6]

王佳玉,徐兵河,田丽军,等.乳腺癌肝转移的临床病程与预后分析[J].中华肿瘤杂志,2006,28(8):612.

[7]

陈云兰,赵金奇.多西紫杉醇联合卡培他滨治疗乳腺癌肝转移的临床观察[J].现代肿瘤学,2012,20(10):2082.

[8]

SCOKETTI M,ARCANGELI S,TOLLI A,et al.Is atereotactic body radiation therapy an attractive option for unreastotable liver metastases a prelininary report from a phase 2 trial[J].Radiat Oncol Biolphys,2013,86(2):336.

[9]

EVANI SJ,PRABHU RG,GNANARUBAN V,et al.Moneytes mediate metastaic breast tumor cell adhesion to endothelium under flow[J].FASEB J,2013,27(8):3017.

[10]

CHUAT C,SAXENA A,LIAUW W,et al.Hepatic resection for metastic breast cancer:a sytematic review[J].Ew J Cancer,2011,47(15):2282.

[11]

FASOL U,FROST A,BUCHERT M,et al.Vascular and pharmacokinetic effects of EndoTAG-1 in patients with advanced cancer and liver metastasis[J].Ann Oncol,2012,23(4):1030.

[12]

TABARIES S,OUELLET V,HSU BE,et al.Granulocytic immune infiltrates are essential for the efficient formation of breast cancer liver metastases[J].Breast Cancer Res,2015,27(3):11.

[13]

饶智国,高建飞,秦必成,等.全身化疗联合肝动脉栓塞化疗治疗乳腺癌术后肝转移的临床疗效观察[J].现代肿瘤学,2013,21(9):1994.

[14]

LIEDTKE C,HESS KR,KAM J,et al.The prognostic impact of age in patients with triple-negative breast cancer[J].Breast Cancer Res Treat,2013,138(2):591.

[15]

GE QD,LV N,KENG YN,et al.Clinical characteristics and survival analysis of breast cancer molecular subtypes with hespatic metastastes[J].Asian Pacific J Cancer Prevention,2012,13(4):5081.

[16]

DUAN XF,DONG NN,ZHANG T,et al.The prognostic analysis of clinical breast cancer subtypes among patients with liver metastases from breast cancer[J].J Clin Oncol,2013,18(1):26.

[17]

SCHOELLHAMMER HF,HSU F,VITO C,et al.Complete pathologic response of HER2-positive breast cancer liver metastasis with dual anti-HER2 antagonism[J].BMC Cancer,2014,4(14):1471.